Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer

Area of Science:

• Oncology
• Urology

Background:

• Non-Muscle-Invasive Bladder Cancer (NMIBC) presents significant challenges with high recurrence and progression rates.
• Intravesical Bacillus Calmette-Guérin (BCG) is the standard treatment but has limitations including efficacy, shortages, and contraindications.
• The need for effective bladder-sparing alternatives is critical, especially for patients unsuitable for radical cystectomy.

Purpose of the Study:

• To review recent advancements in bladder-sparing therapies for NMIBC.
• To highlight novel agents and combination regimens currently in development or recently approved.
• To emphasize the importance of comparative studies and real-world evidence in optimizing treatment strategies.

Main Methods:

• Review of recent clinical trial data and FDA approvals for NMIBC therapies.
• Analysis of emerging agents such as UGN-102, nadofaragene firadenovec, TAR-200, and nogapendekin alfa inbakicept.
• Discussion of ongoing trials involving TAR-210, cretostimogene, and combination regimens.

Main Results:

• Several novel intravesical therapies show promise for both low-grade/intermediate-risk and BCG-unresponsive NMIBC.
• UGN-102 is indicated for low-grade/intermediate-risk disease.
• Nadofaragene firadenovec, TAR-200, and nogapendekin alfa inbakicept are FDA-approved for BCG-unresponsive NMIBC.
• Ongoing trials are evaluating new agents and combination strategies.

Conclusions:

• The landscape of NMIBC treatment is rapidly evolving with new bladder-sparing options.
• Future research should focus on comparative effectiveness, optimal sequencing, and quality-of-life outcomes.
• These advancements offer potential to improve outcomes and preserve bladder function in NMIBC patients.